Author Correction: Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils

1. These authors contributed equally: Xiaochen Wang, Maosheng Cheng, Shuang Chen.

Authors and Affiliations

1. Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

   Xiaochen Wang, Maosheng Cheng, Shuang Chen, Caihua Zhang, Rongsong Ling, Shuqing Qiu, Ke Chen, Wenbin Lei & Demeng Chen

2. State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

   Bin Zhou

3. Department of Head and Neck Surgery, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

   Qiuli Li

4. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China

   Demeng Chen

Corresponding authors

Correspondence to Bin Zhou, Qiuli Li, Wenbin Lei or Demeng Chen.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions